Sign up to save your podcasts
Or
Share Professor Kausik Ray - Lower Is Better: Novel Therapeutic Strategies Targeting PCSK9 for Reducing LDL-C Levels in Patients With Hyperlipidemia and ASCVD
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Professor Kausik Ray - Lower Is Better: Novel Therapeutic Strategies Targeting PCSK9 for Reducing LDL-C Levels in Patients With Hyperlipidemia and ASCVD
Go online to PeerView.com/KXB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in hyperlipidemia discuss clinical evidence and guideline recommendations for the treatment of hyperlipidemia, for both primary and secondary prevention of CV events in patients with ASCVD. Upon completion of this activity, participants should be better able to: Summarize current clinical evidence and guideline recommendations for the treatment of hyperlipidemia, both for primary and secondary prevention of cardiovascular events in patients with ASCVD, Identify novel mechanisms of action and safety-efficacy evidence for approved and emerging investigational lipid-lowering therapies that target PCSK9, Select an appropriate lipid-lowering therapy including available and emerging agents, alone or in combination for providing guideline-directed LDL-C reduction and cardiovascular risk reduction in patients with high-risk ASCVD.
View all episodes
By PVI, PeerView Institute for Medical Education
5
33 ratings
Go online to PeerView.com/KXB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in hyperlipidemia discuss clinical evidence and guideline recommendations for the treatment of hyperlipidemia, for both primary and secondary prevention of CV events in patients with ASCVD. Upon completion of this activity, participants should be better able to: Summarize current clinical evidence and guideline recommendations for the treatment of hyperlipidemia, both for primary and secondary prevention of cardiovascular events in patients with ASCVD, Identify novel mechanisms of action and safety-efficacy evidence for approved and emerging investigational lipid-lowering therapies that target PCSK9, Select an appropriate lipid-lowering therapy including available and emerging agents, alone or in combination for providing guideline-directed LDL-C reduction and cardiovascular risk reduction in patients with high-risk ASCVD.
More shows like PeerView Heart, Lung & Blood CME/CNE/CPE Video Podcast
View all
PeerView Endocrinology & Diabetes CME/CNE/CPE Audio Podcast
5 Listeners
PeerView Heart, Lung & Blood CME/CNE/CPE Audio Podcast
3 Listeners
PeerView Gastroenterology CME/CNE/CPE Audio Podcast
3 Listeners
PeerView Neuroscience & Psychiatry CME/CNE/CPE Audio Podcast
11 Listeners
PeerView Immunology & Transplantation CME/CNE/CPE Audio Podcast
5 Listeners
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast
28 Listeners
PeerView Oncology & Hematology CME/CNE/CPE Video Podcast
9 Listeners
PeerView Gastroenterology CME/CNE/CPE Video Podcast
3 Listeners
PeerView Internal Medicine CME/CNE/CPE Video Podcast
2 Listeners
PeerView Neuroscience & Psychiatry CME/CNE/CPE Video Podcast
4 Listeners
PeerView Endocrinology & Diabetes CME/CNE/CPE Video Podcast
3 Listeners
PeerView Infectious Diseases CME/CNE/CPE Audio Podcast
5 Listeners
PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Audio Podcast
5 Listeners
PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Video Podcast
2 Listeners
PeerView Infectious Diseases CME/CNE/CPE Video Podcast
0 Listeners
PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
9 Listeners
PeerView Immunology & Transplantation CME/CNE/CPE Video Podcast
2 Listeners
PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast
12 Listeners
PeerView Clinical Pharmacology CME/CNE/CPE Video
2 Listeners